Salvage radiotherapy after prostatectomy

A 61-year-old engineer had a radical prostatectomy 2 years ago. The specimen showed grade group 3, extension outside the prostate and a positive surgical margin, with negative lymph nodes. PSA became undetectable after surgery. Now, in 3 consecutive tests, it rose from 0.08 to 0.14 and then to 0.21 ng/mL. He has no symptoms and asks whether he can wait for PSA to reach 1, as he heard from a friend. The scene is fictional and was written for teaching.

This text uses the case as a clinical reasoning scenario for students and health professionals. The topic is salvage radiotherapy after prostatectomy: when to indicate it, how to plan it and when to add hormonal blockade. The basis is the RADICALS-RT, GETUG-AFU 17 and RAVES trials, the ARTISTIC meta-analysis and the European urology guideline. It does not replace your service's protocol. If you play the case of the day on NEXO, you will recognize the challenge: low PSA looks calm, but the moment to act can pass.

Key points

• After prostatectomy, PSA that rises on 2 consecutive measurements calls for discussing salvage radiotherapy.
• Three randomized trials and the ARTISTIC meta-analysis showed no advantage of routine adjuvant radiotherapy over early salvage.
• Adjuvant radiotherapy brought more urinary and bowel side effects.
• The EAU guideline recommends not waiting for a PSA value to start and giving at least 64 Gy as soon as the decision is made.
• Adding hormonal blockade to salvage improved outcomes in randomized trials, with side effects of its own.

Why this is a reasoning scenario

The engineer's question is common and reasonable. A PSA of 0.21 ng/mL is low, he feels well and the treatment has side effects. But the EAU guideline recommends not waiting for a PSA threshold before treating: once salvage is decided, it should be done as soon as possible (EAU guideline, treatment chapter). The post on signs, symptoms and history helps you hear what lies behind the question, and the post on clinical decision-making reminds you that waiting is also a decision.

The scene also trains reasoning over time. A single PSA does not say much; the sequence of values, the pathology of the specimen and the time since surgery say much more. The engineer has a positive margin and extraprostatic extension, factors that were among the criteria of the trials on radiotherapy timing (Vale and colleagues, 2020).

What the scene teaches

The scene trains six habits. The first is recognizing biochemical recurrence. The second is knowing why routine adjuvant radiotherapy lost ground. The third is not waiting for PSA to rise a lot. The fourth is deciding when PSMA PET changes management. The fifth is weighing hormonal blockade. The sixth is explaining side effects with numbers.

What is not at stake

The text does not discuss the choice of initial treatment for localized cancer, which is the topic of another text in the series, nor metastatic disease. The post on diagnostic uncertainty helps when imaging does not show where the disease is.

The PSA that starts rising again

Recurrence and persistence

The guideline separates PSA that starts rising again after becoming undetectable from PSA that never became undetectable after surgery (EAU guideline, treatment chapter). Persistent PSA is a sign of worse prognosis and may indicate low-volume metastatic disease already present (EAU guideline, treatment chapter). In an analysis of RTOG 9601, men with persistent PSA had more metastatic progression at 10 years than those with recurrence, 29 versus 10 percent (EAU guideline, treatment chapter). The engineer had undetectable PSA, which places him in the recurrence group.

When PSA is a concern

After prostatectomy, the PSA threshold that best predicts metastases is above 0.4 ng/mL and rising, but the guideline acknowledges that, with ultrasensitive tests, rises well below that already worry patients (EAU guideline, treatment chapter). It recommends interpreting the PSA rise with the EAU biochemical recurrence risk groups and offering PSA follow-up to low-risk men (EAU guideline, treatment chapter). The post on differential diagnosis helps read each PSA value as a clue, not as a verdict.

Adjuvant or early salvage

The question the studies asked

For many years, men with adverse pathology received radiotherapy right after surgery, the so-called adjuvant radiotherapy. Three randomized studies compared this strategy with observation and early salvage at the first sign of a PSA rise: RADICALS-RT, RAVES and GETUG-AFU 17 (Vale and colleagues, 2020). The three had different primary outcomes, and the ARTISTIC meta-analysis was planned to pool their results (Vale and colleagues, 2020).

The results

The table summarizes the three studies and the meta-analysis, with data from the EAU guideline and the open publications (EAU guideline, treatment chapter).

Study	Patients	Salvage when	Main result	Source
RADICALS-RT	1396	PSA above 0.1 ng/mL	10-year biochemical progression-free survival of 76 versus 75 percent; distant metastasis-free rate of 93 versus 90 percent, with no significant difference	(EAU guideline, treatment chapter)
RAVES	333, closed before the target of 470	PSA above 0.2 ng/mL	5-year biochemical progression-free survival of 86 versus 87 percent	(EAU guideline, treatment chapter)
GETUG-AFU 17	424, closed before the target of 718	PSA of 0.1 ng/mL, with 6 months of hormone blockade	5-year event-free survival of 92 versus 90 percent	(EAU guideline, treatment chapter)
ARTISTIC	2153 across the three studies	As per each study	Hazard ratio of 0.95 for event-free survival, with no difference at 5 years	(Vale and colleagues, 2020)

In the meta-analysis, 5-year event-free survival was around 88 percent in both groups, and only 39 percent of the men in the early salvage group had received radiotherapy by the time of the analysis (Vale and colleagues, 2020). The authors concluded that routine adjuvant radiotherapy does not improve event-free survival (Vale and colleagues, 2020). In other words, watching with PSA and treating at the first sign of a rise spares radiotherapy for many men.

A natural question is whether any subgroup benefits from the adjuvant approach. In ARTISTIC, the effect of radiotherapy timing did not vary significantly by Gleason score, seminal vesicle invasion, surgical margin or CAPRA-S risk group (Vale and colleagues, 2020). The men included were mostly stage pT3a or pT3b, 80 percent, and had a positive margin in 71 percent, that is, they were precisely the men who previously received adjuvant treatment (Vale and colleagues, 2020). The subgroup analysis has limited power, but it did not point to a group in which routine adjuvant treatment clearly beat early salvage.

The first analysis of RADICALS-RT

In the first analysis, with a median of 4.9 years, RADICALS-RT showed no benefit of adjuvant radiotherapy: the hazard ratio for biochemical progression-free survival was 1.10, with no significant difference (Parker and colleagues, 2020). At 5 years, 7 percent of the adjuvant group and 8 percent of the salvage group had started hormone blockade outside the protocol (Parker and colleagues, 2020). Grade 3 or 4 hematuria in the first 2 years occurred in 3 percent of the adjuvant group and in less than 1 percent of the salvage group (Parker and colleagues, 2020). The authors concluded that the analysis showed no advantage of adjuvant treatment in biochemical control or in delaying hormone blockade (Parker and colleagues, 2020).

The long follow-up of RADICALS-RT

With a median of 7.8 years, RADICALS-RT recorded distant metastasis or death from prostate cancer in 80 of 1396 participants, 32 in the adjuvant group and 48 in the salvage group, with a hazard ratio of 0.68 and a non-significant difference (Parker and colleagues, 2024). Overall survival also did not differ, with a hazard ratio of 0.98 (Parker and colleagues, 2024). In the salvage group, the men who received radiotherapy started with a median PSA of 0.2 ng/mL (Parker and colleagues, 2024). The authors concluded that the data reinforce observation after prostatectomy, with salvage reserved for recurrence (Parker and colleagues, 2024).

When adjuvant is still debated

The guideline still suggests offering adjuvant radiotherapy to men without positive lymph nodes with grade group 4 or 5 and stage pT3, with or without a positive margin (EAU guideline, treatment chapter). It recommends not prescribing adjuvant hormonal blockade to men without positive lymph nodes (EAU guideline, treatment chapter). The engineer has grade group 3, and observation with PSA, as he had already been doing, was reasonable. The post about diagnostic pause helps review the pathology before deciding.

How to plan salvage

Do not wait

The guideline recommends offering early salvage radiotherapy, with intensity modulation and image guidance, to men with 2 consecutive PSA rises (EAU guideline, treatment chapter). It also recommends not waiting for a PSA threshold and giving at least 64 Gy as soon as the decision is made (EAU guideline, treatment chapter). The engineer, with 3 rising values, meets that criterion.

The role of PSMA PET

The guideline suggests performing PSMA PET if PSA is above 0.2 ng/mL and if the result could change management (EAU guideline, treatment chapter). In the PSMA-SRT study, the scan changed important decisions in just over a third of the men who were going to have salvage radiotherapy, 33 of 102 (Armstrong and colleagues, 2024). In a phase 2 study, intensification of radiotherapy guided by PSMA PET increased failure-free survival from 69 to 84 percent, with a hazard ratio of 0.46, at a median of 37 months (Belliveau and colleagues, 2025).

With another tracer, fluciclovine, the EMPIRE-1 study randomized 165 men and showed 3-year failure-free survival of 75.5 percent with PET-guided radiotherapy, versus 63.0 percent with conventional imaging (Jani and colleagues, 2021). These studies show that molecular imaging helps choose the target, but they do not point to a PSA value from which waiting is safe.

Salvage planning can follow the steps below.

• Confirm the PSA rise on consecutive measurements.
• Review the pathology of the specimen and the PSA after surgery.
• Request PSMA PET if PSA is above 0.2 and the result could change management.
• Define the target, the prostate bed and, if indicated, the pelvic lymph nodes.
• Discuss adding hormonal blockade and its duration.

A clinical practice study compared real salvage decisions with the criteria of the trials and found differences between what the trials tested and what is done day to day (Bettoli and colleagues, 2024). The post about interprofessional clinical reasoning reminds us that urology, radiotherapy and nuclear medicine need to decide together.

When to add hormonal blockade

RTOG 9601

RTOG 9601 randomized men with rising PSA after prostatectomy to salvage radiotherapy with bicalutamide 150 mg per day for 24 months or placebo (Shipley and colleagues, 2017). Among 760 evaluable patients, with a median PSA of 0.6 ng/mL, 12-year overall survival was 76.3 versus 71.3 percent, with a hazard ratio of 0.77 (Shipley and colleagues, 2017). Death from prostate cancer at 12 years was 5.8 versus 13.4 percent (Shipley and colleagues, 2017). Gynecomastia occurred in 69.7 percent with bicalutamide and in 10.9 percent with placebo (Shipley and colleagues, 2017).

With a median follow-up of 18.7 years, 18-year overall survival was 52.9 versus 43.1 percent, with an adjusted hazard ratio of 0.82 (Lukka and colleagues, 2025). Distant metastases at 18 years were 21.8 versus 30.6 percent (Lukka and colleagues, 2025). The benefit in metastases was greater in the subgroups with more aggressive disease, such as an entry PSA of 1.5 to 4.0 ng/mL or a Gleason score of 8 to 10 (Lukka and colleagues, 2025).

Who benefits most

In the long-term follow-up of RTOG 9601, among men with an entry PSA of 1.5 to 4.0 ng/mL, metastases at 18 years were 17.4 percent with bicalutamide versus 40.6 percent with placebo (Lukka and colleagues, 2025). Among men with a Gleason score of 8 to 10, they were 24.3 versus 53.6 percent (Lukka and colleagues, 2025). These numbers help explain why the decision about hormonal blockade depends on each man's risk: the absolute gain is greater when the disease is more aggressive.

The effects of hormonal blockade

In RTOG 9601, hot flashes were similar in both groups, with grade 1 in 16.6 percent with bicalutamide and 14.1 percent with placebo (Shipley and colleagues, 2017). Gynecomastia was much more frequent with bicalutamide, as described above (Shipley and colleagues, 2017). The study had no measures to prevent gynecomastia, because it was placebo-controlled (Shipley and colleagues, 2017). In practice, these effects come up in the conversation before prescribing.

The SPPORT

SPPORT randomized men to radiotherapy of the prostate bed alone, with 4 to 6 months of hormonal blockade, or with hormonal blockade and radiotherapy of the pelvic lymph nodes (Pollack and colleagues, 2022). Among 1716 eligible patients, freedom from progression at 5 years was 70.9, 81.3 and 87.4 percent in the three arms (Pollack and colleagues, 2022). Adding the pelvic lymph nodes to hormonal blockade increased freedom from progression at 5 years by 6.1 points (Pollack and colleagues, 2022).

What the guideline recommends

The guideline suggests offering hormonal therapy together with salvage radiotherapy to men with biochemical recurrence (EAU guideline, treatment chapter). The choice of who receives it and for how long depends on risk, PSA, pathology and the patient's health. For the engineer, with grade group 3, a positive margin and a still low PSA, the conversation about short hormonal blockade is reasonable, weighing the adverse effects.

Adverse effects and the conversation with the patient

The effects of radiotherapy

In RADICALS-RT, adjuvant radiotherapy had more adverse effects, especially grade 1 and 2, and late toxicity remained higher (Parker and colleagues, 2024). Grade 3 or 4 urethral stricture occurred in 6 percent of participants (Parker and colleagues, 2024). Patient-reported incontinence was worse at 1 year in the adjuvant group, and fecal incontinence was worse at 1 year and still different at 10 years (Parker and colleagues, 2024). In GETUG-AFU 17, late grade 2 or higher urinary toxicity was 27 versus 7 percent, and erectile dysfunction was 28 versus 8 percent, both higher with adjuvant radiotherapy (EAU guideline, treatment chapter).

The conversation with the engineer

The answer to his question is not yes or no without explanation. Waiting for PSA to reach 1 is not the strategy the studies tested; early salvage started with a low PSA, around 0.2 ng/mL (Parker and colleagues, 2024). It is worth explaining that a rising PSA after surgery indicates disease that has come back, that treating early was what the studies used and that the guideline recommends not waiting. Then explain the role of PSMA PET before planning, present the urinary, bowel and sexual effects of radiotherapy and discuss hormonal blockade, with its gains and its effects.

It also helps to ask what he understands by waiting and what worries him most. Some men fear the incontinence they already had after surgery; others, the loss of erection; others, time away from work. Knowing what weighs most for him allows you to present the numbers that matter for his decision.

The studies measured biochemical progression, metastasis and survival, and did not promise a cure. It is worth telling the patient what is known and what is still being monitored. The post about clinical deterioration on the ward reminds us that following a trend, and not a single value, is what allows action in time.

How NEXO helps train this reasoning

In NEXO, the case of the day is fictional, with a real clinical presentation and up to six progressive clues, and you propose the diagnosis by looking for the ICD-10 code. Biochemical recurrence is a good exercise because the decision depends on a sequence of tests and on time. The post about case-based learning explains why this format fixes knowledge.

Three exercises with cases

Change the PSA after surgery. Say what changes if the engineer's PSA had never become undetectable.

Change the pathology. Say what changes if the specimen showed grade group 5 and stage pT3b.

Change the imaging. Say what you would do if PSMA PET showed an avid pelvic lymph node.

The post about simulation of a consultation helps train the conversation about the timing of salvage treatment.

The limits on using the game are described on the NEXO economy page. If you research the teaching of clinical reasoning, the page for researchers explains how to get in touch. Professionals who write or review cases find information under curation and creators, and institutions can learn about the proposal on the partnerships page.

Frequently asked questions

Does every prostatectomy with a positive margin need radiotherapy right afterwards?

Not routinely. The studies did not show an advantage of adjuvant over early salvage treatment (Vale et al., 2020).

When should salvage radiotherapy start?

With 2 consecutive PSA rises, without waiting for a threshold (EAU guideline, treatment chapter).

Is PSMA PET mandatory?

The guideline suggests the scan with PSA above 0.2 ng/mL if the result could change management (EAU guideline, treatment chapter).

Why add hormonal blockade?

In RTOG 9601 and SPPORT, adding it improved outcomes, with adverse effects of its own (Shipley et al., 2017) (Pollack et al., 2022).

Does salvage radiotherapy cure?

The studies measured progression, metastasis and survival, and did not define cure. Long-term results are good for many men (Parker et al., 2024).

Final checklist

• I separated persistent PSA from recurrence.
• I confirmed 2 consecutive PSA rises.
• I reviewed the pathology of the specimen.
• I avoided waiting for a PSA threshold.
• I considered PSMA PET.
• I set a dose of at least 64 Gy.
• I discussed hormonal blockade.
• I explained the adverse effects with numbers.

Want to practice the reasoning with progressive clues? Play the case of the day.

References

1. Armstrong WR, Kishan AU, Booker KM, et al. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774). Eur Urol. 2024. PMID 38290964.
2. Belliveau C, Saad F, Duplan D, et al. Prostate-Specific Membrane Antigen PET-Guided Intensification of Salvage Radiotherapy After Radical Prostatectomy: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2025. PMID 41037308.
3. Bettoli P, Röling E, Russo M, et al. Shaping Clinical Policy for Salvage Radiotherapy After Radical Prostatectomy in Prostate Cancer: Bridging the Gap Between Clinical Trials and Daily Practice. Cancer Med. 2024. PMID 39485266.
4. European Association of Urology. Treatment - EAU Guidelines on Prostate Cancer - Uroweb. Accessed on 24/10/2026. Official source.
5. Jani AB, Schreibmann E, Goyal S, et al. (18)F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial. Lancet. 2021. PMID 33971152.
6. Lukka HR, Pugh SL, Shipley WU, et al. Long-Term Results of NRG/RTOG 9601, a Randomized Trial of Radiation With or Without Antiandrogens in Patients Receiving Salvage Prostate Bed Radiation Therapy Postprostatectomy. Int J Radiat Oncol Biol Phys. 2025. PMID 40752653.
7. Parker CC, Clarke NW, Cook AD, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet. 2020. PMID 33002429.
8. Parker CC, Petersen PM, Cook AD, et al. Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047). Ann Oncol. 2024. PMID 38583574.
9. Pollack A, Karrison TG, Balogh AG, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022. PMID 35569466.
10. Shipley WU, Seiferheld W, Lukka HR, et al. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med. 2017. PMID 28146658.
11. Vale CL, Fisher D, Kneebone A, et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet. 2020. PMID 33002431.